Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
TTPH's Cash-to-Debt is ranked higher than
78% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. TTPH: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
TTPH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.79  Med: No Debt Max: No Debt
Current: No Debt
0.79
No Debt
Equity-to-Asset 0.87
TTPH's Equity-to-Asset is ranked higher than
86% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. TTPH: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
TTPH' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.71  Med: 0.87 Max: 0.95
Current: 0.87
-7.71
0.95
Interest Coverage No Debt
TTPH's Interest Coverage is ranked higher than
73% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. TTPH: No Debt )
Ranked among companies with meaningful Interest Coverage only.
TTPH' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: -3.26
Beneish M-Score: 14.34
WACC vs ROIC
22.63%
1571.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -441.49
TTPH's Operating Margin % is ranked lower than
66% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. TTPH: -441.49 )
Ranked among companies with meaningful Operating Margin % only.
TTPH' s Operating Margin % Range Over the Past 10 Years
Min: -11581.62  Med: -722.86 Max: -184.25
Current: -441.49
-11581.62
-184.25
Net Margin % -432.40
TTPH's Net Margin % is ranked lower than
67% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. TTPH: -432.40 )
Ranked among companies with meaningful Net Margin % only.
TTPH' s Net Margin % Range Over the Past 10 Years
Min: -11656.22  Med: -733.59 Max: -198.51
Current: -432.4
-11656.22
-198.51
ROE % -61.84
TTPH's ROE % is ranked lower than
63% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. TTPH: -61.84 )
Ranked among companies with meaningful ROE % only.
TTPH' s ROE % Range Over the Past 10 Years
Min: -1245.47  Med: -67.97 Max: -45.03
Current: -61.84
-1245.47
-45.03
ROA % -54.23
TTPH's ROA % is ranked lower than
70% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. TTPH: -54.23 )
Ranked among companies with meaningful ROA % only.
TTPH' s ROA % Range Over the Past 10 Years
Min: -79.11  Med: -53.34 Max: -42.27
Current: -54.23
-79.11
-42.27
ROC (Joel Greenblatt) % -5762.75
TTPH's ROC (Joel Greenblatt) % is ranked lower than
81% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. TTPH: -5762.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TTPH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24570.09  Med: -8622.34 Max: -1760.04
Current: -5762.75
-24570.09
-1760.04
3-Year Revenue Growth Rate -13.20
TTPH's 3-Year Revenue Growth Rate is ranked lower than
65% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. TTPH: -13.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TTPH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -18.6 Max: -4.7
Current: -13.2
3-Year EBITDA Growth Rate -2.60
TTPH's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. TTPH: -2.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TTPH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: -2.6 Max: 67.5
Current: -2.6
-50.4
67.5
3-Year EPS without NRI Growth Rate -1.80
TTPH's 3-Year EPS without NRI Growth Rate is ranked lower than
58% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. TTPH: -1.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TTPH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.8 Max: 67.6
Current: -1.8
0
67.6
GuruFocus has detected 3 Warning Signs with Tetraphase Pharmaceuticals Inc TTPH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TTPH's 30-Y Financials

Financials (Next Earnings Date: 2019-03-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

TTPH Guru Trades in Q3 2017

Paul Tudor Jones 100,000 sh (New)
Jim Simons 333,585 sh (+132.16%)
» More
Q4 2017

TTPH Guru Trades in Q4 2017

Jim Simons 592,493 sh (+77.61%)
Paul Tudor Jones Sold Out
» More
Q1 2018

TTPH Guru Trades in Q1 2018

Mario Gabelli 30,000 sh (New)
Jim Simons 952,185 sh (+60.71%)
» More
Q2 2018

TTPH Guru Trades in Q2 2018

Chuck Royce 155,800 sh (New)
Mario Gabelli 35,000 sh (+16.67%)
Jim Simons 623,885 sh (-34.48%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:TTPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XPAR:IVA, XTER:HAE, XKRX:002800, XCNQ:IN, XKRX:001360, OSTO:ORX, NAS:GALT, TSE:4539, HKSE:00911, ORSE:OLF1R, LSE:SPH, ROCO:4132, HKSE:06896, XKRX:131030, OTCPK:GSRX, ROCO:6576, XKRX:009300, TPE:4119, XCNQ:TER, OTCPK:CBIS » details
Traded in other countries:7TP.Germany,
Headquarter Location:USA
Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It creates novel antibiotics for serious and life-threatening multidrug-resistant infections. Its pipeline products are ERAVACYCLINE, TP-271, and TP-6076.

Tetraphase Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It creates novel antibiotics for serious and life-threatening multidrug-resistant infections. Its pipeline products are ERAVACYCLINE, TP-271, and TP-6076.

Top Ranked Articles about Tetraphase Pharmaceuticals Inc

Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call
Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States
Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections
Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) and TP-6076 Data at IDWeek 2018

Ratios

vs
industry
vs
history
PB Ratio 1.00
TTPH's PB Ratio is ranked higher than
83% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. TTPH: 1.00 )
Ranked among companies with meaningful PB Ratio only.
TTPH' s PB Ratio Range Over the Past 10 Years
Min: 0.66  Med: 2.46 Max: 15.1
Current: 1
0.66
15.1
PS Ratio 5.59
TTPH's PS Ratio is ranked higher than
58% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TTPH: 5.59 )
Ranked among companies with meaningful PS Ratio only.
TTPH' s PS Ratio Range Over the Past 10 Years
Min: 0.51  Med: 23.7 Max: 136.54
Current: 5.59
0.51
136.54
EV-to-EBIT -0.02
TTPH's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. TTPH: -0.02 )
Ranked among companies with meaningful EV-to-EBIT only.
TTPH' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.1  Med: -1.6 Max: 4.3
Current: -0.02
-20.1
4.3
EV-to-EBITDA -0.02
TTPH's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. TTPH: -0.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
TTPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -20.1  Med: -1.6 Max: 4.4
Current: -0.02
-20.1
4.4
EV-to-Revenue 0.15
TTPH's EV-to-Revenue is ranked higher than
84% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. TTPH: 0.15 )
Ranked among companies with meaningful EV-to-Revenue only.
TTPH' s EV-to-Revenue Range Over the Past 10 Years
Min: -5.9  Med: 15.4 Max: 139.2
Current: 0.15
-5.9
139.2
Current Ratio 7.28
TTPH's Current Ratio is ranked higher than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. TTPH: 7.28 )
Ranked among companies with meaningful Current Ratio only.
TTPH' s Current Ratio Range Over the Past 10 Years
Min: 1.43  Med: 7.96 Max: 21.44
Current: 7.28
1.43
21.44
Quick Ratio 7.28
TTPH's Quick Ratio is ranked higher than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. TTPH: 7.28 )
Ranked among companies with meaningful Quick Ratio only.
TTPH' s Quick Ratio Range Over the Past 10 Years
Min: 1.43  Med: 7.96 Max: 21.44
Current: 7.28
1.43
21.44
Days Sales Outstanding 55.27
TTPH's Days Sales Outstanding is ranked higher than
57% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. TTPH: 55.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
TTPH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.27  Med: 129.65 Max: 365
Current: 55.27
55.27
365

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.60
TTPH's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. TTPH: -18.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TTPH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -371.5  Med: -22.6 Max: -13
Current: -18.6
-371.5
-13

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.20
TTPH's Price-to-Net-Cash is ranked higher than
89% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. TTPH: 1.20 )
Ranked among companies with meaningful Price-to-Net-Cash only.
TTPH' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.93  Med: 2.48 Max: 12.87
Current: 1.2
0.93
12.87
Price-to-Net-Current-Asset-Value 1.09
TTPH's Price-to-Net-Current-Asset-Value is ranked higher than
91% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. TTPH: 1.09 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
TTPH' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.89  Med: 2.33 Max: 11.6
Current: 1.09
0.89
11.6
Price-to-Tangible-Book 1.08
TTPH's Price-to-Tangible-Book is ranked higher than
87% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. TTPH: 1.08 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TTPH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.88  Med: 2.32 Max: 11.41
Current: 1.08
0.88
11.41
Price-to-Median-PS-Value 0.24
TTPH's Price-to-Median-PS-Value is ranked higher than
87% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. TTPH: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TTPH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.99 Max: 5.28
Current: 0.24
0.02
5.28
Earnings Yield (Greenblatt) % -3488.99
TTPH's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. TTPH: -3488.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TTPH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -23403.3  Med: -16.85 Max: 1690.2
Current: -3488.99
-23403.3
1690.2

More Statistics

Revenue (TTM) (Mil) $17.15
EPS (TTM) $ -1.37
Beta3.24
Volatility72.45%
52-Week Range $1.78 - 6.97
Shares Outstanding (Mil)53.63

Analyst Estimate

Dec18 Dec19 Dec20 Dec21
Revenue (Mil $) 17 12 27 60
EBIT (Mil $)
EBITDA (Mil $) -74 -69 -52 -40
EPS ($) -1.23 -1.04 -0.79 -0.36
EPS without NRI ($) -1.23 -1.04 -0.79 -0.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}